Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
Copyright West LLC. Minimum 15 minutes delayed.
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Gemphire Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
Gemphire Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update